Evidence map›Paper›PMID 27079315›Full record

ArticleTransfusion2016

"Next-generation" mesenchymal stem or stromal cells for the in vivo delivery of bioactive factors: progressing toward the clinic.

Jan A Nolta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jan A NoltaStem Cell Program and Institute for Regenerative Cures, University of California Davis, Sacramento, California.

Funding

Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
MSCs engineered to produce Brain-Derived Neurotrophic Factor for the Treatment of Huntington's diseaseR01NS102486 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Kyle Fink, Jan A. Nolta · 2017 to 2026
$3.7M
Direct cell to cell transfer of microRNA for tissue repairR01GM099688 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2011 to 2015
$2.7M
Training Program in Biomolecular TechnologyT32GM008799 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI LEACH, J. KENT · 2002 to 2016
$2.4M
Functional dissection of human A-MSC vs BM-MSC phenotypeR01HL073256 · NHLBI · WASHINGTON UNIVERSITY · PI NOLTA, JAN A. · 2003 to 2010
$2.3M
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
NCRR NIH HHS S10 RR026825NHLBI NIH HHS R01 HL073256NHLBI NIH HHS T32 HL086350NHLBI NIH HHS T32-HL086350NIGMS NIH HHS R01 GM099688NIGMS NIH HHS R01GM099688NIGMS NIH HHS T32 GM008799NIGMS NIH HHS T32-GM008799NINDS NIH HHS R01 NS102486
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBiological FactorsDisease Models, AnimalDrug Delivery SystemsEvaluation Studies as TopicHumansHuntington DiseaseMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, TransgenicNeovascularization, PhysiologicBiological Factors

Identifiers

PMID27079315
PMCPMC6526951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.